These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33254510)

  • 1. Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19?
    Avcilar H; Eken A
    Med Hypotheses; 2020 Nov; 144():110202. PubMed ID: 33254510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of TLR7 and Innate Immunity as an Efficient Method Against COVID-19 Pandemic: Imiquimod as a Potential Therapy.
    Poulas K; Farsalinos K; Zanidis C
    Front Immunol; 2020; 11():1373. PubMed ID: 32612613
    [No Abstract]   [Full Text] [Related]  

  • 3. Interferon and Toll-Like Receptor 7 Response in COVID-19: Implications of Topical Imiquimod for Prophylaxis and Treatment.
    Szeto MD; Maghfour J; Sivesind TE; Anderson J; Olayinka JT; Mamo A; Runion TM; Dellavalle RP
    Dermatology; 2021; 237(6):847-856. PubMed ID: 34511591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19.
    Angelopoulou A; Alexandris N; Konstantinou E; Mesiakaris K; Zanidis C; Farsalinos K; Poulas K
    Environ Res; 2020 Sep; 188():109858. PubMed ID: 32846644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
    Vasilakos JP; Tomai MA
    Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New perspective in immunotherapy: local imiquimod treatment].
    Kemény L; Nagy N
    Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TLR7 Agonists Display Potent Antiviral Effects against Norovirus Infection via Innate Stimulation.
    Enosi Tuipulotu D; Netzler NE; Lun JH; Mackenzie JM; White PA
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 infection and the antiviral innate immune response.
    Yang H; Lyu Y; Hou F
    J Mol Cell Biol; 2020 Nov; 12(12):963-967. PubMed ID: 33377937
    [No Abstract]   [Full Text] [Related]  

  • 9. Conjugation of a Small-Molecule TLR7 Agonist to Silica Nanoshells Enhances Adjuvant Activity.
    Huang CH; Mendez N; Echeagaray OH; Weeks J; Wang J; Vallez CN; Gude N; Trogler WC; Carson DA; Hayashi T; Kummel AC
    ACS Appl Mater Interfaces; 2019 Jul; 11(30):26637-26647. PubMed ID: 31276378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule agonists of toll-like receptors 7 and 8: a patent review 2014 - 2020.
    Kieffer ME; Patel AM; Hollingsworth SA; Seganish WM
    Expert Opin Ther Pat; 2020 Nov; 30(11):825-845. PubMed ID: 33052748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of TLR7 agonists in modulating COVID-19 severity in subjects with loss-of-function TLR7 variants.
    Naushad SM; Mandadapu G; Ramaiah MJ; Almajhdi FN; Hussain T
    Sci Rep; 2023 Aug; 13(1):13078. PubMed ID: 37567916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldara activates TLR7-independent immune defence.
    Walter A; Schäfer M; Cecconi V; Matter C; Urosevic-Maiwald M; Belloni B; Schönewolf N; Dummer R; Bloch W; Werner S; Beer HD; Knuth A; van den Broek M
    Nat Commun; 2013; 4():1560. PubMed ID: 23463003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toll-like receptor 7/8 agonists stimulate plasmacytoid dendritic cells to initiate T
    Garzorz-Stark N; Lauffer F; Krause L; Thomas J; Atenhan A; Franz R; Roenneberg S; Boehner A; Jargosch M; Batra R; Mueller NS; Haak S; Groß C; Groß O; Traidl-Hoffmann C; Theis FJ; Schmidt-Weber CB; Biedermann T; Eyerich S; Eyerich K
    J Allergy Clin Immunol; 2018 Apr; 141(4):1320-1333.e11. PubMed ID: 28935206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current pharmacological treatments for SARS-COV-2: A narrative review.
    Nittari G; Pallotta G; Amenta F; Tayebati SK
    Eur J Pharmacol; 2020 Sep; 882():173328. PubMed ID: 32603692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice.
    Zhang WW; Matlashewski G
    Infect Immun; 2008 Aug; 76(8):3777-83. PubMed ID: 18474642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antiviral activity of Toll-like receptor 7 and 7/8 agonists.
    Miller RL; Meng TC; Tomai MA
    Drug News Perspect; 2008 Mar; 21(2):69-87. PubMed ID: 18389099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice.
    Heib V; Becker M; Warger T; Rechtsteiner G; Tertilt C; Klein M; Bopp T; Taube C; Schild H; Schmitt E; Stassen M
    Blood; 2007 Aug; 110(3):946-53. PubMed ID: 17446350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod.
    Othoro C; Johnston D; Lee R; Soverow J; Bystryn JC; Nardin E
    Infect Immun; 2009 Feb; 77(2):739-48. PubMed ID: 19047411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
    Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
    J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral and nonviral uses of imiquimod: a review.
    Gupta AK; Cherman AM; Tyring SK
    J Cutan Med Surg; 2004; 8(5):338-52. PubMed ID: 15868314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.